Skip to content
Archive

KOLINPHARMA® launched PROINTEX®, the innovative nutraceutical that marks the start of its new gastroenterology line

PROINTEX® expands the range of products offered by Kolinpharma®, taking the company into a new therapeutic area: gastroenterology.

Thanks to active ingredients such as resveratrol, saffron extract, B vitamins, vitamin D, zinc, calcium and a unique blend of 5 probiotics, PROINTEX® aims to promote intestinal well-being and support digestive and psychological function.

Rita Paola Petrelli, President of KOLINPHARMA, commented: “To date, more than 3 million people in Italy suffer from Irritable Bowel Syndrome (IBS), a condition that affects young people, especially women of working age, and which in its most severe forms can greatly limit social and daily life, heavily affecting quality of life. IBS is a functional disorder which, because of the variety of its symptoms affecting both the gut and the psychological sphere, is increasingly recognised today as a condition involving the gut-brain axis.

We have always looked to the future of nutraceuticals, and this new PROINTEX® project is yet another confirmation of this. This initiative marks a key milestone in Kolinpharma's expansion strategy, reaffirming our ambition for growth and the central role of our R&D department in innovation in the sector."

More news

  1. Kolinpharma® renews its partnership with La Neurologia Italiana: Research and Science at the Service of the Patient
  2. Kolinpharma® and RCS MediaGroup spa with Corriere Salute: together for a new culture of well-being
  3. Kolinpharma in Il Sole 24 Ore’s “Leader della crescita 2026” ranking
Archive